Hematologic malignancies following immune checkpoint inhibition for solid tumors

被引：0
|
作者：
Mick J. M. van Eijs
Lotte E. van der Wagen
Rogier Mous
Roos J. Leguit
Lisette van de Corput
Anne S. R. van Lindert
Britt B. M. Suelmann
Anna M. Kamphuis
Stefan Nierkens
Karijn P. M. Suijkerbuijk
机构：
[1] University Medical Center Utrecht,Department of medical oncology
[2] University Medical Center Utrecht,Center for Translational Immunology
[3] University Medical Center Utrecht,Department of hematology
[4] University Medical Center Utrecht,Department of pathology
[5] University Medical Center Utrecht,Central Diagnostic Laboratory
[6] University Medical Center Utrecht,Department of pulmonology
[7] Princess Máxima Center for Pediatric Oncology,undefined
来源：
Cancer Immunology, Immunotherapy | 2023年 / 72卷
关键词：
Case series; Immune checkpoint inhibitor; Leukemia; Myeloid neoplasms; Second primary cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.
引用
收藏
页码：249 / 255
页数：6
相关论文
共 50 条
  • [1] Hematologic malignancies following immune checkpoint inhibition for solid tumors
    van Eijs, Mick J. M.
    van der Wagen, Lotte E.
    Mous, Rogier
    Leguit, Roos J.
    van de Corput, Lisette
    van Lindert, Anne S. R.
    Suelmann, Britt B. M.
    Kamphuis, Anna M.
    Nierkens, Stefan
    Suijkerbuijk, Karijn P. M.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (01) : 249 - 255
  • [2] Checkpoint inhibition in hematologic malignancies
    Tsumura, Aaron
    Levis, Daniel
    Tuscano, Joseph M.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [3] Immune checkpoint blockade in hematologic malignancies
    Armand, Philippe
    BLOOD, 2015, 125 (22) : 3393 - 3400
  • [4] Biomarkers for checkpoint inhibition in hematologic malignancies
    Atanackovic, Djordje
    Luetkens, Tim
    SEMINARS IN CANCER BIOLOGY, 2018, 52 : 198 - 206
  • [5] Editorial: Checkpoint inhibition in hematologic malignancies
    Pu, Jeffrey J.
    Drabick, Joseph J.
    Prockop, Susan E.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [6] Checkpoint inhibition in pediatric hematologic malignancies
    Davis, Kara L.
    Agarwal, Archana M.
    Verma, Anupam R.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2017, 34 (6-7) : 379 - 394
  • [7] The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies
    Keung, Emily Z.
    Wargo, Jennifer A.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2019, 28 (03) : 369 - +
  • [8] The influence of hematologic malignancies on response to immune checkpoint inhibition in patients with advanced melanoma
    van Not, O. J.
    Van Den Eertwegh, F.
    Haanen, J. B. A. G.
    van Rijn, R. S.
    Aarts, M.
    Van den Berkmortel, F.
    Blank, C. U.
    Boers-Sonderen, M.
    de Groot, J. W. B.
    Hospers, G.
    Kapiteijn, E.
    De Meza, M. M.
    Piersma, D.
    Stevense-den Boer, M.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Wouters, M.
    Blokx, W. A. M.
    Suijkerbuijk, K. P. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S942 - S943
  • [9] Programming the immune checkpoint to treat hematologic malignancies
    Vick, Eric
    Mahadevan, Daruka
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (07) : 755 - 770
  • [10] Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies
    Bilgihan, Muhammed Talha
    Eryigit, Ayse Nur
    Ciftciler, Rafiye
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01): : 23 - 31
12345